Artigo Acesso aberto Revisado por pares

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib

2020; Lippincott Williams & Wilkins; Volume: 38; Issue: 28 Linguagem: Inglês

10.1200/jco.20.00522

ISSN

1527-7755

Autores

Filip Janků, Albiruni R. Abdul Razak, Ping Chi, Michael C. Heinrich, Margaret von Mehren, Robin L. Jones, Kristen N. Ganjoo, Jonathan C. Trent, Hans Gelderblom, Neeta Somaiah, Simin Hu, Oliver Rosen, Ying Su, Rodrigo Ruiz‐Soto, Michael S. Gordon, Suzanne George,

Tópico(s)

Neurofibromatosis and Schwannoma Cases

Resumo

In advanced gastrointestinal stromal tumor (GIST), there is an unmet need for therapies that target both primary and secondary mutations of pathogenic KIT/PDGFRA oncoproteins. Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of

Referência(s)